The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

EP: 1.Overview of RSV Patient Populations

EP: 2.Complications Associated with RSV Infections

EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

EP: 4.RSV: Risk Factors and How It’s Spread

EP: 5.Diagnostic Practices for RSV

EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients

EP: 7.Shared Decision-Making Practices in RSV

EP: 8.Financial and Clinical Benefits of RSV Immunization

Now Viewing

EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

EP: 10.Addressing Vaccine Fatigue

EP: 11.Identifying Patients Eligible for RSV Vaccine

EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines

EP: 13.Improving Insurance Coverage for RSV Vaccines

EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation

EP: 15.Key Takeaways on RSV Vaccination

Video content above is prompted by the following questions:

• What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
• How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
  • What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
• How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
  • How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?